considerations when selecting an egfr inhibitor in metastatic colorectal cancer
Published 10 years ago • 774 plays • Length 7:32Download video MP4
Download video MP3
Similar videos
-
4:00
optimizing treatment with egfr inhibitors in colorectal cancer
-
7:42
egfr-targeted therapy in metastatic colorectal cancer
-
5:09
colorectal cancer: choosing a biologic
-
13:46
choosing between anti-vegf and anti-egfr targeted therapy
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
7:10
upfront egfr therapy in metastatic colorectal cancer
-
13:46
choosing between vegf and egfr targeted therapy in mcrc
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
6:19
clinical development of cetuximab in metastatic colorectal cancer
-
9:00
first- and later-line use of panitumumab in metastatic colorectal cancer
-
6:26
role of the vegf inhibitor aflibercept in metastatic colorectal cancer
-
1:51
dr. peeters discusses the frequency of s492r mutations following egfr inhibition in mcrc
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
7:31
sequencing agents in metastatic colorectal cancer
-
0:15
colon cancer and egfr inhibitors
-
4:15
egfr in metastatic colon cancer
-
6:25
metastatic colorectal cancer markers to inform treatment selection
-
6:01
new drugs in development for metastatic colorectal cancer
-
4:15
second-line therapy options in metastatic colorectal cancer